FDA Approves Kresladi: First Gene Therapy for Rare Immune Disorder

How the Gene Therapy Works

Kresladi uses an autologous ex vivo gene therapy approach, which is among the most technically demanding but also the most clinically promising strategies in genetic medicine. The process involves three steps:

1. Collection: Hematopoietic stem cells (blood-forming stem cells) are harvested from the patient's own bone marrow.
2. Modification: Those cells are exposed ex vivo (outside the body) to a lentiviral vector that delivers a functional copy of the ITGB2 gene. The lentiviral vector integrates the corrected gene into the stem cells' DNA.
3. Re-infusion: The corrected stem cells are returned to the patient, where they engraft in the bone marrow and begin producing functional CD18.

The autologous approach, using the patient's own cells rather than a donor's, eliminates the risk of GvHD, the potentially fatal immune rejection that is the primary risk of the allogeneic bone marrow transplants that have been the standard of care for Severe LAD-I. Allogeneic transplants also require finding a closely matched donor, which is difficult for rare genetic conditions affecting small patient populations that may not have extensive donor registry representation.

The lentiviral vector used in Kresladi integrates permanently into the patient's DNA, meaning the corrected gene persists in the stem cell population and is passed to daughter cells as those stem cells divide. This is in contrast to some newer gene editing approaches (like base editing or CRISPR) where the modification machinery does not persist. For a condition like Severe LAD-I where the goal is permanent restoration of a protein that the patient's own genetic code cannot produce, permanent integration is a feature rather than a concern, provided the integration sites do not disrupt other essential genes.

Clinical Data: Nine Patients, Sustained Results

Clinical trials for ultra-rare pediatric diseases are inherently small. There are not enough patients in the world to run a randomized controlled trial of the kind that might be standard for a common condition. The FDA's accelerated approval pathway acknowledges this reality by allowing approval based on surrogate endpoints, measurable biological outcomes that are reasonably likely to predict clinical benefit, rather than requiring long-term survival data that would take years to accumulate in a nine-patient cohort.

The surrogate endpoint for Kresladi was CD18 and CD11a surface expression on white blood cells, measured by flow cytometry. In patients with Severe LAD-I, these proteins are absent or present at less than 2% of normal levels. After Kresladi treatment, all nine patients in the trial showed restored expression at levels consistent with normal immune function. The expression was sustained through month 24 of follow-up, the longest timepoint available at the time of the application.

What we do not yet know from this data is whether the immune restoration translates to normal infection rates and life expectancy over the full course of the patients' lives. The accelerated approval pathway creates a post-marketing commitment: Rocket Pharma is required to continue following these nine patients and any subsequently treated patients to confirm that the surrogate endpoint predicts the clinical benefit of reduced infections and survival that motivates the treatment. The FDA can withdraw or modify the approval if post-marketing data does not support the initial findings.

"Kresladi represents a meaningful advance for these patients and families. This is a condition where, without treatment, most children do not survive infancy. A one-time autologous therapy that eliminates the GvHD risk while achieving sustained immune function addresses the core problem in a way the previous standard of care could not."

FDA Center for Biologics Evaluation and Research, accelerated approval statement, March 26, 2026

What Accelerated Approval Means in Practice

FDA accelerated approval is a specific regulatory mechanism designed for conditions with serious unmet medical needs. It allows approval based on surrogate endpoints, with a condition that the manufacturer must complete confirmatory trials demonstrating actual clinical benefit. If those confirmatory trials fail, the FDA can withdraw approval. The accelerated pathway does not mean a less rigorous review of the safety data: it means the primary evidence for efficacy is surrogate endpoints rather than long-term clinical outcomes.

For Severe LAD-I, the unmet need is undeniable. The condition is fatal without treatment. The existing treatment, allogeneic bone marrow transplant, carries mortality risk of its own. A nine-patient trial with sustained 24-month surrogate endpoint data is, in this context, a substantial evidence base relative to the population that exists. The FDA's accelerated approval reflects a considered judgment that the risk-benefit calculation justifies availability now, with continued evidence collection confirming that judgment over time.

This approval sits within a broader pattern in gene therapy regulation. The FDA has approved a small but growing number of gene therapies over the past decade, including Luxturna for inherited retinal dystrophy, Zolgensma for spinal muscular atrophy, and several CAR-T cell therapies. Each approval has added to the regulatory framework for how gene therapies are reviewed, how post-market commitments are structured, and how the agency thinks about the risk-benefit calculation for one-time curative treatments at very high price points.

Access, Pricing, and the Rare Disease Economics Problem

Rocket Pharma has not announced Kresladi's list price at the time of this writing. Gene therapies for ultra-rare pediatric conditions have historically been priced in the range of $1 million to $4 million per treatment, reflecting the small patient population that the development costs must be amortized across, the manufacturing complexity of autologous cell therapy, and the lifetime value of treating a condition that would otherwise require decades of supportive care and multiple hospitalizations.

The pricing of rare disease gene therapies is among the most contested questions in health policy. Payers, including Medicaid programs that cover a disproportionate share of rare disease patients, must decide how to value treatments that provide large benefits to very small numbers of patients. The economics of autologous gene therapy manufacturing, where each batch is patient-specific, are genuinely different from large-scale pharmaceutical manufacturing, and the costs are not trivial.

With approximately 25 new cases per year in the United States, the total addressable market for Kresladi is extremely small. That small market is why the development of this therapy depended on rare disease designation, priority review vouchers, and other regulatory incentives that reduce the financial risk of developing treatments for conditions too rare to support standard pharmaceutical economics. Understanding how these incentives work, and whether they are calibrated correctly to produce the level of rare disease drug development that patients need, is an ongoing policy conversation that this approval illustrates concretely.

The Broader Gene Therapy Landscape

Kresladi's approval adds to a category of approved gene therapies that has grown substantially over the past five years. The FDA's expanding experience with the accelerated approval pathway for gene therapies, the development of improved vector manufacturing techniques, and the growing understanding of long-term safety for lentiviral and adeno-associated virus-based therapies have collectively reduced the barriers to gene therapy development for rare genetic conditions.

The pipeline for other primary immune deficiencies is substantial. Adenosine deaminase-deficient SCID, Wiskott-Aldrich syndrome, chronic granulomatous disease, and several other rare conditions have gene therapy programs in various stages of clinical development. Each approval, including Kresladi's, adds to the manufacturing and regulatory infrastructure that makes subsequent approvals more straightforward.

The longer-term trajectory of gene therapy points toward conditions that are much more common than Severe LAD-I. The technical platform, the lentiviral-mediated ex vivo gene correction of hematopoietic stem cells, is applicable to any condition caused by a single gene defect in the blood-forming system. Sickle cell disease and beta-thalassemia, which affect millions of people worldwide, have gene therapies in late-stage development and early commercial deployment. The lessons learned from treating a handful of patients with Severe LAD-I are directly applicable to scaling those programs.

As we covered in our reporting on the evolving biotech market in 2026, gene therapy's transition from experimental to approved medicine across an increasing range of conditions is one of the defining stories of this era of biological science. Kresladi is a single approval for 25 annual patients, but it represents the accumulation of decades of basic research into lentiviral biology, stem cell transplantation, and the molecular genetics of primary immune deficiencies, translated into a treatment that can save lives that would previously have been cut short in infancy.